Categories: CancerNews

RaySearch Laboratories: Year-end report 2024

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

STOCKHOLM, Feb. 21, 2025 /PRNewswire/ —

FOURTH QUARTER (OCTOBER – DECEMBER 2024)

  • Order intake SEK 305.0 M (317.7)
  • Net sales SEK 322.7 (299.6) 
  • Operating profit SEK 73.6 M (44.4)
  • Profit after tax SEK 60.0 M (31.5)
  • Earnings per share before/after dilution SEK 1.75 (0.92)
  • Cash flow from operating activities SEK 102.9 M (115.8) 
  • Order backlog SEK 1,813.2 M (1,864.4) at the end of the period.

TWELVE MONTHS (JANUARY – DECEMBER 2024)

  • Order intake SEK 1,087.2 M (1,004.2)
  • Net sales SEK 1,192.0 M (1,022.2)
  • Operating profit SEK 260.5 M (114.9)
  • Profit after tax SEK 203.5 M (81.6)
  • Earnings per share before/after dilution SEK 5.94 (2.38)
  • Cash flow from operating activities SEK 485.2 M (455.9)
  • The Board of Directors proposes a dividend for the full-year 2024 of SEK 3.00 (0.70).

SIGNIFICANT EVENTS DURING THE FOURTH QUARTER

  • GenesisCare UK has placed an order for RayStation.
  • Number of radiotherapy clinics in China using RayStation now exceeds 100.
  • Three centers in the French Unicancer network select RayStation.
  • Institut Curie in France select RayStation for treatment planning with protons.
  • RayStation is in clinical use for proton-arc therapy at Trento Proton Therapy Center in Italy.

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

  • In January the Polish company Medim placed an order for the product DrugLog.
  • In October 2024, Nina Grönberg was appointed new CFO for RaySearch Laboratories AB (publ), Nina took up her position January 27.

FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf, CEO, Tel: +46 8 510 530 00, e-mail: johan.lof@raysearchlabs.com
Nina Grönberg, CFO, Tel: +46 8 510 530 00, e-mail: nina.gronberg@raysearchlabs.com

The information contained in this year-end report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on February 21, 2025, at 7:45 a.m.

WEBCAST

CEO Johan Löf and CFO Nina Grönberg will present RaySearch’s year-end report for January-December 2024 at a webcast to be held in English on Friday, February 21, 2025, at 10:00-10:30 a.m. CET.

Link to webcast: RaySearch Year-end report 2024

This information was brought to you by Cision http://news.cision.com.

https://news.cision.com/raysearch-laboratories/r/year-end-report-2024,c4109202

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/raysearch-laboratories-year-end-report-2024-302382164.html

SOURCE RaySearch Laboratories

Staff

Recent Posts

How Medical Malpractice Cases Work in Florida: What Victims Need to Know

MIAMI, March 29, 2025 /PRNewswire/ -- The Law Offices of Jason Turchin, a national personal injury…

1 hour ago

Tempus Exhibits 4 Abstracts at the 2025 American College of Cardiology Annual Meeting

CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to…

10 hours ago

Best Legal Steroids for Bulking and Muscle Growth 2025 – Buy Steroid Alternatives From CrazyBulk

NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- Use D-Bal to pack on serious muscle…

10 hours ago

Legal Steroids For Muscle Growth 2025: Best Steroids For (Bodybuilding & Bulking) By CrazyBulk in USA

NEW YORK, March 29, 2025 (GLOBE NEWSWIRE) -- While there is a huge range of…

10 hours ago

Junshi Biosciences Announces 2024 Full Year Financial Results and Provides Corporate Updates

SHANGHAI, March 28, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences,” HKEX:…

10 hours ago

Turnstone Biologics Corp. Reports Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 28, 2025 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”)…

10 hours ago